Literature DB >> 34244730

Use of Vedolizumab in Immune Checkpoint Inhibitor-associated Enterocolitis.

Molly L Stone1, Erin M Forster2.   

Abstract

Entities:  

Keywords:  checkpoint-inhibitor enterocolitis; pembrolizumab; vedolizumab

Mesh：

Substances：

Year:  2021        PMID： 34244730      PMCID： PMC8826165          DOI： 10.1093/ibd/izab159

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   7.290


× No keyword cloud information.
  3 in total

1.  AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review.

Authors:  Michael Dougan; Yinghong Wang; Alberto Rubio-Tapia; Joseph K Lim
Journal:  Gastroenterology       Date:  2020-10-17       Impact factor: 22.682

2.  Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.

Authors:  Hamzah Abu-Sbeih; Faisal S Ali; Dana Alsaadi; Joseph Jennings; Wenyi Luo; Zimu Gong; David M Richards; Aline Charabaty; Yinghong Wang
Journal:  J Immunother Cancer       Date:  2018-12-05       Impact factor: 13.751

3.  Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.

Authors:  Daniel H Johnson; Chrystia M Zobniw; Van A Trinh; Junsheng Ma; Roland L Bassett; Noha Abdel-Wahab; Jaime Anderson; Jennifer E Davis; Jocelyn Joseph; Marc Uemura; Ali Noman; Hamzah Abu-Sbeih; Cassian Yee; Rodabe Amaria; Sapna Patel; Hussein Tawbi; Isabella C Glitza; Michael A Davies; Michael K Wong; Scott Woodman; Wen-Jen Hwu; Patrick Hwu; Yinghong Wang; Adi Diab
Journal:  J Immunother Cancer       Date:  2018-10-11       Impact factor: 13.751
  3 in total
  1 in total

Review 1.  Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis.

Authors:  Sae Ohwada; Keisuke Ishigami; Noriyuki Akutsu; Hiroshi Nakase
Journal:  Biomedicines       Date:  2022-06-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.